A crucial second pivotal trial in uterine fibroids fails to dispel concerns about the company’s linzagolix.
Two years after Abbvie’s disappointing launch of Orilissa Myovant hails the development of something much better.
Phase III data for Obseva's uterine fibroid project linzagolix need to prove its safety, while Inventiva tests its pan-PPAR agonist lanifibranor in Nash.
Incremental data revealed at the conference could give Mirati, Exelixis and Seattle Genetics renewed hope.
The German start-up must navigate the hazards that have felled other surgical robot developers while simultaneously dealing with a more crowded market.
The pivotal portion of bardoxolone’s Cardinal study can’t match earlier data, but is still sufficient for filing.